Pramila Krishnamurthy
A5011143459- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Hematological disorders and diagnostics
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Virus-based gene therapy research
- Pneumocystis jirovecii pneumonia detection and treatment
- Fungal Infections and Studies
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Eosinophilic Disorders and Syndromes
- Hemoglobinopathies and Related Disorders
- Antifungal resistance and susceptibility
- Vascular Tumors and Angiosarcomas
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Respiratory viral infections research
King's College Hospital
2009-2024
King's College Hospital NHS Foundation Trust
2010-2024
Queen Elizabeth University Hospital
2024
King's College London
2011-2022
Cambridge University Hospitals NHS Foundation Trust
2018-2022
Addenbrooke's Hospital
2016-2020
HCG Cancer Centre
2016
King's College - North Carolina
2012
New York University
2011
Otemae Hospital
2011
Summary This study aimed to determine the incidence/prognostic impact of TP 53 mutation in 318 myelodysplastic syndrome ( MDS ) patients, and correlate changes cytogenetics, single nucleotide polymorphism array karyotyping clinical outcome. The median age was 65 years (17–89 years) follow‐up 45 months [95% confidence interval CI 27–62 months]. mutations occurred 30 (9·4%) exclusively isolated del5q (19%) complex karyotype CK with ‐5/5q‐(72%), correlated International Prognostic Scoring...
Abstract Germ line DDX41 variants have been implicated in late-onset myeloid neoplasms (MNs). Despite an increasing number of publications, many important features DDX41-mutated MNs remain to be elucidated. Here we performed a comprehensive characterization MNs, enrolling total 346 patients with pathogenic/likely-pathogenic (P/LP) germ and/or somatic mutations from 9082 MN patients, together 525 first-degree relatives and wild-type (WT) patients. P/LP explained ∼80% known predisposition...
To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics.
Abstract Patients with FLT3 -mutated AML have a high relapse rate and suboptimal outcomes. Many co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR those destined to can be identified or rising levels of MRD, called molecular failure. This provides window pre-emptive intervention, but there is little evidence guide treatment. The use inhibitors (FLT3i) appears attractive their has not yet been evaluated. We 56 patients treated FLT3i at mutation was an ITD in 52,...
Assessment of measurable residual disease (MRD) by quantitative reverse transcription polymerase chain reaction is strongly prognostic in patients with NPM1-mutated acute myeloid leukemia (AML) treated intensive chemotherapy; however, there are no data regarding its utility venetoclax-based nonintensive therapy, despite high efficacy this genotype. We analyzed the impact NPM1 MRD an international real-world cohort 76 previously untreated AML who achieved complete remission (CR)/CR incomplete...
Allogeneic stem-cell transplant allows for the delivery of curative graft-versus-leukemia (GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance T-cell chimerism, measurable residual disease (MRD) and blast HLA-DR expression may inform whether GVL effectiveness is reduced. We report here prognostic impact these biomarkers allografted AML/MDS. One hundred eighty-seven from FIGARO, a randomized trial reduced-intensity conditioning regimens AML/MDS, were alive...
Relapse occurs in 30%-50% of recipients T cell-depleted (TCD) reduced-intensity conditioned (RIC) hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). Despite limited published supportive data, donor lymphocyte infusion (DLI) is used preemptively (pDLI) to improve chimerism prevent relapse, therapeutically (tDLI) after disease recurrence. We evaluated the efficacy toxicity pDLI tDLI 113 patients TCD (alemtuzumab, n = 99;...
Summary A joint working group established by the Haemato‐oncology subgroup of British Committee for Standards in Haematology, Society Bone Marrow Transplantation and UK Clinical Virology Network has reviewed available literature made recommendations diagnosis management respiratory viral infections patients with haematological malignancies or those undergoing haematopoietic stem cell transplantation. This guideline includes diagnosis, prevention treatment adults children. The suggestions are...
Higher-risk MDS (HR-MDS) with RARA gene overexpression is a subset of HR-MDS patients (pts) an actionable target for tamibarotene, oral and selective RARα agonist. Tamibarotene in combination azacitidine (AZA) showed high complete remission (CR) rates AML. SELECT-MDS-1 (NCT04797780) was Phase 3 study comparing the activity tamibarotene/ to placebo/AZA newly diagnosed (ND) pts overexpression. Eligible had confirmed by blood-based assay, untreated higher-risk features IPSS-R bone marrow blast...
Venetoclax with azacitidine is the standard of care for patients AML who are unfit intensive chemotherapy, however uncertainties remain regarding treatment schedule, accurate prognostication and outcomes treated outside clinical trials. The option venetoclax low-dose cytarabine (LDAC) also available, it not clear which may be a useful alternative. Here we report large real-world cohort 654 in 53 UK hospitals either (n=587) or LDAC (n=67). Median age was 73 59% had de novo AML. Most received...
This document represents an update of the British Society Haematology Guideline published in 2014 due to advances understanding biology and therapy myelodysplastic syndromes (MDS).1 The objective these guidelines is provide healthcare professionals with clear guidance on management adult patients MDS. Individual circumstances may dictate alternative approach. A separate for (BSH) guideline covers Diagnosis Evaluation Prognosis Adult MDS which alongside this Guideline. good-practice paper...
Allogeneic hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning (RIC) offers a potential cure for patients myelodysplastic syndrome (MDS) who are ineligible standard-intensity regimens. Previously published data from our institution suggest excellent outcomes at 1 yr using uniform fludarabine, busulfan, and alemtuzumab-based regimen. Here we report long-term follow-up of 192 MDS acute myelogenous leukemia (AML) secondary to (MDS-AML) transplanted this protocol,...
Background: Allogeneic haematopoietic stem-cell transplant is a potentially curative option for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients. Post-transplant cyclophosphamide administration allows selection of haploidentical donors in patients who are eligible the procedure, but do not have fully matched donor, since it can overcome HLA barrier. There still an active debate on whether intensification conditioning regimen necessary with when peripheral...
Pre-emptive DLI (pDLI) is an effective strategy in lowering the risk of relapse without significantly increasing graft-versus-host disease (GVHD) case T cell lineage mixed chimerism (MC) post allogeneic transplant hematological malignancies. Many patients, however, fail to receive timely pDLI and have dismal outcomes, which are not taken into consideration. We compared long-term outcomes 106 patients having MC after day 60 undergoing stem allograft for acute leukemia from unrelated donor...
Classical veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication post allogeneic hematopoietic stem cell transplantation (HSCT). Before the recently revised EBMT criteria, Baltimore and modified Seattle criteria failed to recognize of late-onset VOD. We present real-world experience from large UK transplant center reporting on VOD/SOS in consecutive HSCT adult patients (n = 530), transplanted for hematological cancers. identified 27 treated with...
Ineffective induction of T cell mediated immunity in older individuals remains a persistent challenge for vaccine development. Thus, there is need more efficient and sophisticated adjuvants that will complement novel strategies the elderly. To this end, we have investigated previously optimized, combined molecular adjuvant, CASAC (Combined Adjuvant Synergistic Activation Cellular immunity), incorporating two complementary Toll-like receptor agonists, CpG polyI:C, class-II epitope, interferon...
This document represents an update of the British Society Haematology guideline published in 2014 due to advances understanding biology and therapy myelodysplastic syndromes (MDS).1 The objective these guidelines is provide healthcare professionals with clear guidance on diagnosis evaluation prognosis adult patients MDS. A separate BSH covers Management Adult MDS which alongside this guideline. good practice paper detailing management chronic myelomonocytic leukaemia (CMML) will follow not...